2009
DOI: 10.1016/j.vaccine.2009.07.083
|View full text |Cite
|
Sign up to set email alerts
|

A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

3
37
0

Year Published

2012
2012
2019
2019

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 28 publications
(40 citation statements)
references
References 10 publications
3
37
0
Order By: Relevance
“…[111][112][113][114] Other studies found that MDCK cell-derived vaccines were at least equivalent, and sometimes better and more efficacious as compared to ECEderived antigens. 111,112,[114][115][116][117][118][119][120] In one instance, it was reported that at risk adult and elderly subjects who did not respond serologically to a previous ECE-derived vaccine responded better when boosted with MDCK cell-derived vaccine as compared to an ECE-based vaccine. 121 Since the early 1990s, reports of more than 20 clinical studies involving greater than 20,000 subjects in over a dozen countries, as well as large-scale immunization programs have further confirmed the safety and immunogenicity of MDCK cell-derived influenza vaccines.…”
Section: Mdck Cell-derived Influenza Vaccines: the Final Joust?mentioning
confidence: 99%
See 4 more Smart Citations
“…[111][112][113][114] Other studies found that MDCK cell-derived vaccines were at least equivalent, and sometimes better and more efficacious as compared to ECEderived antigens. 111,112,[114][115][116][117][118][119][120] In one instance, it was reported that at risk adult and elderly subjects who did not respond serologically to a previous ECE-derived vaccine responded better when boosted with MDCK cell-derived vaccine as compared to an ECE-based vaccine. 121 Since the early 1990s, reports of more than 20 clinical studies involving greater than 20,000 subjects in over a dozen countries, as well as large-scale immunization programs have further confirmed the safety and immunogenicity of MDCK cell-derived influenza vaccines.…”
Section: Mdck Cell-derived Influenza Vaccines: the Final Joust?mentioning
confidence: 99%
“…As far as safety is concerned, overall AEs have been reported in up to 84% of the subjects, 112,114,116,117,[122][123][124][125] with a higher incidence in adults (60-84%) as compared to children (50-60%) and lowest (typically 15-25%, but sometimes up to 50%) in the elderly. 114,122,123,125 Total local AEs have ranged from 10% to 84%, 112,[114][115][116][117]122,124,126 again, typically higher in adults than in children, and lowest in the elderly. 114,116,118,122 Local AEs are also higher in the case of adjuvanted vaccine formulations as compared to unadjuvanted vaccine.…”
Section: Mdck Cell-derived Influenza Vaccines: the Final Joust?mentioning
confidence: 99%
See 3 more Smart Citations